Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced m...
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
About this item
Full title
Author / Creator
Yuan, Jianda , Adamow, Matthew , Ginsberg, Brian A , Rasalan, Teresa S , Ritter, Erika , Gallardo, Humilidad F , Xu, Yinyan , Pogoriler, Evelina , Terzulli, Stephanie L , Kuk, Deborah , Panageas, Katherine S , Ritter, Gerd , Sznol, Mario , Halaban, Ruth , Jungbluth, Achim A , Allison, James P , Old, Lloyd J , Wolchok, Jedd D and Gnjatic, Sacha
Publisher
United States: National Academy of Sciences
Journal title
Language
English
Formats
Publication information
Publisher
United States: National Academy of Sciences
Subjects
More information
Scope and Contents
Contents
Ipilimumab, a monoclonal antibody against cytotoxic T lymphocyte antigen 4 (CTLA-4), has been shown to improve survival in patients with advanced metastatic melanoma. It also enhances immunity to NY-ESO-1, a cancer/testis antigen expressed in a subset of patients with melanoma. To characterize the association between immune response and clinical ou...
Alternative Titles
Full title
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
Authors, Artists and Contributors
Author / Creator
Adamow, Matthew
Ginsberg, Brian A
Rasalan, Teresa S
Ritter, Erika
Gallardo, Humilidad F
Xu, Yinyan
Pogoriler, Evelina
Terzulli, Stephanie L
Kuk, Deborah
Panageas, Katherine S
Ritter, Gerd
Sznol, Mario
Halaban, Ruth
Jungbluth, Achim A
Allison, James P
Old, Lloyd J
Wolchok, Jedd D
Gnjatic, Sacha
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1539448049
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1539448049
Other Identifiers
ISSN
0027-8424
E-ISSN
1091-6490
DOI
10.1073/pnas.1110814108
